Skip to content
HowShorted

Viridian Therapeutics, Inc.\DE short interest in 2023

In 2023, Viridian Therapeutics, Inc.\DE's disclosed short interest ran from 6.08% of shares outstanding on 13 Jan 2023 to 16.46% on 29 Dec 2023, a change of +10.38 percentage points. The year's high was 21.66% on 31 Aug 2023 and its low 5.88% on 31 Jan 2023, averaging 13.61% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.35 days on 31 Aug 2023. Full history: Viridian Therapeutics, Inc.\DE.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Viridian Therapeutics, Inc.\DE in 2023

2023 in figures

Start of year
6.08% (13 Jan 2023)
End of year
16.46% (29 Dec 2023)
Change
+10.38 pp
High
21.66% (31 Aug 2023)
Low
5.88% (31 Jan 2023)
Average
13.61%
Highest days to cover
24.35 (31 Aug 2023)
SEC filings marked
7

Every report in 2023

Viridian Therapeutics, Inc.\DE short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20236.08%2.78
31 Jan 20235.88%4.84
15 Feb 20236.62%5.66
28 Feb 20236.60%5.62
15 Mar 20236.49%4.79results (8-K), 10-K filed
31 Mar 20238.04%6.14
14 Apr 20238.28%7.38
28 Apr 20238.13%5.82
15 May 202310.17%5.91results (8-K), 10-Q filed
31 May 202313.27%8.96
15 Jun 202314.14%10.75
30 Jun 202315.74%6.94
14 Jul 202317.46%6.33
31 Jul 202314.51%8.20
15 Aug 202319.83%13.5410-Q filed
31 Aug 202321.66%24.35
15 Sep 202321.39%11.74
29 Sep 202321.61%21.68
13 Oct 202317.49%8.82
31 Oct 202318.69%9.21
15 Nov 202315.75%8.9210-Q filed, results (8-K)
30 Nov 202316.17%12.22
15 Dec 202316.09%8.92
29 Dec 202316.46%8.43

See also: Viridian Therapeutics, Inc.\DE's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.